ENDRA Life Sciences (NDRA) Tops Q4 EPS by 1c

ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08).

Cash and cash equivalents were $9.5 million as of December 31, 2021.

For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Verizon Communications (VZ) Tops Q2 EPS by 2c, Misses on Revenue, Tops on Postpaid Adds
• Lockheed Martin (LMT) PT Raised to $581 at UBS on Revenue Growth Momentum